Hyaluronidase Improves Doxorubicin Delivery in Osteosarcoma
Author Information
Author(s): Eikenes L, Tari M, Tufto I, Bruland ØS, de Lange Davies C
Primary Institution: The Norwegian University of Science and Technology
Hypothesis
Hyaluronidase might induce a transcapillary pressure gradient, thereby improving the tumour uptake and distribution of liposomal doxorubicin within the tumour.
Conclusion
Hyaluronidase reduces a major barrier for drug delivery by inducing a transcapillary pressure gradient, which improves the therapeutic outcome of liposomal doxorubicin.
Supporting Evidence
- Hyaluronidase reduced interstitial fluid pressure in a nonlinear dose-dependent manner.
- Maximum interstitial fluid pressure reduction of approximately 50% was found after injection of 1500 U hyaluronidase.
- Hyaluronidase induced a transcapillary pressure gradient, resulting in a four-fold increase in the tumour uptake of liposomal doxorubicin.
- Statistical analysis showed that the maximum reduction in interstitial fluid pressure was significantly lower than control tumours injected with PBS.
Takeaway
Hyaluronidase helps medicine get into tumors better by making it easier for the medicine to move around inside the tumor.
Methodology
The study measured interstitial fluid pressure and microvascular pressure in human osteosarcoma xenografts after administering hyaluronidase and analyzed the distribution of liposomal doxorubicin using confocal laser scanning microscopy.
Limitations
The study was conducted in animal models, which may not fully replicate human responses.
Participant Demographics
7–9-week-old athymic female BALB/c nu/nu mice
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website